{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:24:50Z","timestamp":1789809890846,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1186\/s12920-019-0481-z","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T08:07:28Z","timestamp":1552550848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exome, transcriptome and miRNA analysis don\u2019t reveal any molecular markers of TKI efficacy in primary CML patients"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4962-6947","authenticated-orcid":false,"given":"Alexander V.","family":"Lavrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-1789","authenticated-orcid":false,"given":"Ekaterina Yu.","family":"Chelysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6440-0500","authenticated-orcid":false,"given":"Elmira P.","family":"Adilgereeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-0816","authenticated-orcid":false,"given":"Oleg A.","family":"Shukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-3048","authenticated-orcid":false,"given":"Svetlana A.","family":"Smirnikhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-4542","authenticated-orcid":false,"given":"Konstantin S.","family":"Kochergin-Nikitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-9297","authenticated-orcid":false,"given":"Valentina D.","family":"Yakushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-6221","authenticated-orcid":false,"given":"Grigory A.","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7924-4945","authenticated-orcid":false,"given":"Sergey V.","family":"Mordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-2371","authenticated-orcid":false,"given":"Anna G.","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3133-8018","authenticated-orcid":false,"given":"Sergey I.","family":"Kutsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"issue":"Suppl 11","key":"481_CR1","first-page":"S257","volume":"18","author":"W Yin","year":"2012","unstructured":"Yin W, Penrod JR, Maclean R, Lakdawalla DN, Philipson T. Value of survival gains in chronic myeloid leukemia. Am J Manag Care. 2012;18(Suppl 11):S257\u201364.","journal-title":"Am J Manag Care"},{"key":"481_CR2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Br\u00fcmmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, M\u00fcller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spie\u00df B, Balleisen L, Goebeler MC, H\u00e4nel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, K\u00f6hne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, M\u00fcller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Tr\u00fcmper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Sch\u00e4fer E, Hochhaus A, Hasford J, for the SAKK and the German CML study group. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"issue":"2","key":"481_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16(2):122\u201331.","journal-title":"Cancer Control"},{"issue":"4","key":"481_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12185-014-1649-0","volume":"100","author":"N Iriyama","year":"2014","unstructured":"Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, Kodaira H, Inoue M, Takei M. The European treatment and outcome study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. Int J Hematol. 2014;100(4):379\u201385.","journal-title":"Int J Hematol"},{"issue":"8","key":"481_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","volume":"32","author":"J Francis","year":"2015","unstructured":"Francis J, Dubashi B, Sundaram R, Pradhan SC, Chandrasekaran A. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib. Med Oncol. 2015;32(8):213.","journal-title":"Med Oncol"},{"issue":"1","key":"481_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cas.12321","volume":"105","author":"E Yamamoto","year":"2014","unstructured":"Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, Hashimoto C, Itabashi M, Ishibashi D, Nakajima Y, Tachibana T, Kawasaki R, Kuwabara H, Koharazawa H, Yamazaki E, Tomita N, Sakai R, Fujita H, Kanamori H, Ishigatsubo Y. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105\u20139.","journal-title":"Cancer Sci"},{"issue":"Suppl 2","key":"481_CR7","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1007\/s00277-015-2327-x","volume":"94","author":"B Hanfstein","year":"2015","unstructured":"Hanfstein B, M\u00fcller MC, Hochhaus A. Response-related predictors of survival in CML. Ann Hematol. 2015;94(Suppl 2):S227\u201339.","journal-title":"Ann Hematol"},{"issue":"1","key":"481_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25(1):7\u201322.","journal-title":"Leukemia."},{"issue":"2","key":"481_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013;98(2):193\u2013200.","journal-title":"Haematologica."},{"key":"481_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-016-0837-5","volume":"14","author":"Q Zheng","year":"2016","unstructured":"Zheng Q, Cao J, Hamad N, Kim HJ, Moon JH, Sohn SK, Jung CW, Lipton JH, Kim DD. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. J Transl Med. 2016;14:82.","journal-title":"J Transl Med"},{"key":"481_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","volume":"59","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Zhang Z, Ahn J, Choi S, Szardenings M, Lipton JH, Kim HJ, Kim Dong Hwan D. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk Res. 2017;59:142\u20138.","journal-title":"Leuk Res"},{"issue":"10","key":"481_CR12","doi-asserted-by":"publisher","first-page":"E623","DOI":"10.1002\/ajh.24865","volume":"92","author":"L Mologni","year":"2017","unstructured":"Mologni L, Piazza R, Khandelwal P, Pirola A, Gambacorti-Passerini C. Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase CML patients. Am J Hematol. 2017;92(10):E623\u20135.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"481_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12863-015-0308-7","volume":"17","author":"AV Lavrov","year":"2016","unstructured":"Lavrov AV, Chelysheva EY, Smirnikhina SA, Shukhov OA, Turkina AG, Adilgereeva EP, Kutsev SI. Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia. BMC Genet. 2016;17(Suppl 1):14.","journal-title":"BMC Genet"},{"issue":"8","key":"481_CR14","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","volume":"20","author":"O Frank","year":"2006","unstructured":"Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, Schwindel U, Zheng C, M\u00fcller MC, Gretz N, Hehlmann R, Hochhaus A, Seifarth W. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006;20(8):1400\u20137.","journal-title":"Leukemia."},{"issue":"6","key":"481_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","volume":"20","author":"R Villuendas","year":"2006","unstructured":"Villuendas R, Steegmann JL, Poll\u00e1n M, Tracey L, Granda A, Fern\u00e1ndez-Ruiz E, Casado LF, Mart\u00ednez J, Mart\u00ednez P, Lombard\u00eda L, Villal\u00f3n L, Odriozola J, Piris MA. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 2006;20(6):1047\u201354.","journal-title":"Leukemia."},{"issue":"1\u20132","key":"481_CR16","first-page":"1","volume":"386","author":"FF Costa","year":"2007","unstructured":"Costa FF. Non-coding RNAs: lost in translation? Gene. 2007;386(1\u20132):1\u201310.","journal-title":"Gene."},{"issue":"4","key":"481_CR17","doi-asserted-by":"publisher","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","volume":"7","author":"OH Rokah","year":"2012","unstructured":"Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Shpilberg O. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7(4):e35501.","journal-title":"PLoS One"},{"issue":"5","key":"481_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s13402-012-0095-3","volume":"35","author":"S Babashah","year":"2012","unstructured":"Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). 2012;35(5):317\u201334.","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"481_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/ijlh.12351","volume":"37","author":"P Fallah","year":"2015","unstructured":"Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F, Hosseini Rad SM, Kohram M, Teimori Naghadeh H, Soleimani M. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015;37(4):560\u20138.","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"481_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","volume":"76","author":"K Kotagama","year":"2015","unstructured":"Kotagama K, Chang Y, Mangone M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Dev Res. 2015;76(6):278\u201385.","journal-title":"Drug Dev Res"},{"key":"481_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1476-4598-8-69","volume":"8","author":"ES Jos\u00e9-En\u00e9riz","year":"2009","unstructured":"Jos\u00e9-En\u00e9riz ES, Rom\u00e1n-G\u00f3mez J, Jim\u00e9nez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodr\u00edguez-Otero P, Calasanz MJ, Pr\u00f3sper F, Agirre X. MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69.","journal-title":"Mol Cancer"},{"issue":"6","key":"481_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4149\/neo_2015_115","volume":"62","author":"D Jurkovicova","year":"2015","unstructured":"Jurkovicova D, Lukackova R, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Chovanec M. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma. 2015;62(6):949\u201358.","journal-title":"Neoplasma."},{"issue":"2 Pt B","key":"481_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","volume":"356","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 2015;356(2 Pt B):597\u2013605.","journal-title":"Cancer Lett"},{"issue":"2","key":"481_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","volume":"360","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 2015;360(2):245\u201356.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"481_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2014.02.008","volume":"53","author":"AF Ferreira","year":"2014","unstructured":"Ferreira AF, Moura LG, Tojal I, Ambr\u00f3sio L, Pinto-Sim\u00f5es B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Blood Cells Mol Dis. 2014;53(1\u20132):47\u201355.","journal-title":"Blood Cells Mol Dis"},{"key":"481_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood."},{"key":"481_CR27","unstructured":"J.P. Sinnwell, D.J. Schaid, Haplo Stats (version 1.7.7) Statistical Methods for Haplotypes When Linkage Phase is Ambiguous [Internet]. Rochester MN USA 55904, Mayo Clinic Division of Health Sciences Research. \n                    https:\/\/cran.r-project.org\/web\/packages\/haplo.stats\/vignettes\/manualHaploStats.pdf\n                    \n                  . Accessed 05 July 2018."},{"issue":"Web Server issu","key":"481_CR28","doi-asserted-by":"publisher","first-page":"W498","DOI":"10.1093\/nar\/gks494","volume":"40","author":"IS Vlachos","year":"2012","unstructured":"Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;40(Web Server issue):W498\u2013504.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"481_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O'Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"481_CR30","doi-asserted-by":"publisher","first-page":"e78582","DOI":"10.1371\/journal.pone.0078582","volume":"8","author":"V Augis","year":"2013","unstructured":"Augis V, Airiau K, Josselin M, Turcq B, Mahon FX, Belloc F. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib. PLoS One. 2013;8(11):e78582.","journal-title":"PLoS One"},{"key":"481_CR31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/sj.leu.2404310","volume":"20","author":"Y-J Chung","year":"2006","unstructured":"Chung Y-J, Kim T-M, Kim D-W, Namkoong H, Kim HK, Ha S-A, Kim S, Shin SM, Kim JH, Lee YJ, Kang HM, Kim JW. Gene expression signatures associated with the resistance to imatinib. Leukemia. 2006;20:1542\u201350.","journal-title":"Leukemia."},{"issue":"1","key":"481_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/cgt.2015.63","volume":"23","author":"M Sharifi","year":"2016","unstructured":"Sharifi M, Salehi R. Blockage of miR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia. Cancer Gene Ther. 2016;23(1):29\u201335.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"481_CR33","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1111\/j.1582-4934.2010.01213.x","volume":"15","author":"DD Feng","year":"2011","unstructured":"Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, Chen YQ. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011;15(10):2164\u201375.","journal-title":"J Cell Mol Med"},{"key":"481_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13059-014-0568-y","volume":"16","author":"EL Lim","year":"2015","unstructured":"Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, Mottok A, Ennishi D, Johnson NA, Steidl C, Connors JM, Morin RD, Gascoyne RD, Marra MA. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol. 2015;16:18.","journal-title":"Genome Biol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-019-0481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12920-019-0481-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-019-0481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T20:12:47Z","timestamp":1583957567000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-019-0481-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":34,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1186\/s12920-019-0481-z","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"13 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"37"}}